How to buy Adaptimmune Therapeutics stock

Adaptimmune Therapeutics plc is a biotechnology business based in the US. Adaptimmune Therapeutics shares (ADAP) are listed on the NASDAQ and all prices are listed in US Dollars. Adaptimmune Therapeutics employs 420 staff and has a trailing 12-month revenue of around USD$3.2 million.

How to buy shares in Adaptimmune Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Adaptimmune Therapeutics. Find the stock by name or ticker symbol: ADAP. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Adaptimmune Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Adaptimmune Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Adaptimmune Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Adaptimmune Therapeutics share price

Use our graph to track the performance of ADAP stocks over time.

Adaptimmune Therapeutics shares at a glance

• Key figures

Information last updated 2021-02-23.

52-week range	USD$2 - USD$12.48
50-day moving average	USD$6.0109
200-day moving average	USD$6.4356
Wall St. target price	USD$11.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.967

Buy Adaptimmune Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Adaptimmune Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Adaptimmune Therapeutics plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adaptimmune Therapeutics financials

Revenue TTM	USD$3.2 million
Gross profit TTM	USD$-96,379,000
Return on assets TTM	-22.96%
Return on equity TTM	-46.9%
Profit margin	0%
Book value	$2.431
Market capitalisation	USD$920.9 million

TTM: trailing 12 months

Shorting Adaptimmune Therapeutics shares

There are currently 1.4 million Adaptimmune Therapeutics shares held short by investors – that's known as Adaptimmune Therapeutics's "short interest". This figure is 8.1% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Adaptimmune Therapeutics shares can be evaluated.

Adaptimmune Therapeutics's "short interest ratio" (SIR)

Adaptimmune Therapeutics's "short interest ratio" (SIR) is the quantity of Adaptimmune Therapeutics shares currently shorted divided by the average quantity of Adaptimmune Therapeutics shares traded daily (recently around 1.3 million). Adaptimmune Therapeutics's SIR currently stands at 1.11. In other words for every 100,000 Adaptimmune Therapeutics shares traded daily on the market, roughly 1110 shares are currently held short.

However Adaptimmune Therapeutics's short interest can also be evaluated against the total number of Adaptimmune Therapeutics shares, or, against the total number of tradable Adaptimmune Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptimmune Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Adaptimmune Therapeutics shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Adaptimmune Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adaptimmune Therapeutics.

Find out more about how you can short Adaptimmune Therapeutics stock.

Adaptimmune Therapeutics share price volatility

Over the last 12 months, Adaptimmune Therapeutics's shares have ranged in value from as little as $2 up to $12.48. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptimmune Therapeutics's is 2.215. This would suggest that Adaptimmune Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Adaptimmune Therapeutics overview

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Frequently asked questions

• What percentage of Adaptimmune Therapeutics is owned by insiders or institutions?

  Currently 0.218% of Adaptimmune Therapeutics shares are held by insiders and 84.045% by institutions.

• How many people work for Adaptimmune Therapeutics?

  Latest data suggests 420 work at Adaptimmune Therapeutics.

• When does the fiscal year end for Adaptimmune Therapeutics?

  Adaptimmune Therapeutics's fiscal year ends in December.

• Where is Adaptimmune Therapeutics based?

  Adaptimmune Therapeutics's address is: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX

• What is Adaptimmune Therapeutics's ISIN number?

  Adaptimmune Therapeutics's international securities identification number is: US00653A1079

• What is Adaptimmune Therapeutics's CUSIP number?

  Adaptimmune Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00653A107